IM Cannabis

IMCC

Market cap $1.04M

TORONTO and GLIL YAM, Israel, July 27, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that Mr. Alon Dayan has resigned as a director of the Company for personal reasons.

TORONTO and GLIL YAM, Israel, July 1, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor (the "Lender"). Pursuant to a note purchase agreement between the Company and Lender dated July 1, 2026 (the "July Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$225,000, with an original issuance discount of 10% (the "July Note").

Transaction Expected to Streamline Operations, Retain Israeli Business, Improve Working Capital through debt reduction and Cash Flow While Enabling the Pursuit of New Investment Opportunities as Previously Announced TORONTO and GLIL YAM, Israel, June 18, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a medical cannabis company with operations in Israel and Germany, is pleased to announce that it has entered into a non-binding letter of intent (the "Letter of Intent") with Slil.com Holding Ltd., a privately-held Israeli entity beneficially owned and controlled by Oren Shuster, the Company's Chief Executive Officer, a director and debtholder of IMC ("Slil"), pursuant to which the Company has agreed to sell to Slil its European-focused assets (the "Transaction").

TORONTO and GLIL YAM, Israel, June 9, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that, further to its press releases dated May 7, 2026 and  June 3, 2026, it has filed a resale registration statement on Form F-3 (the "Resale Registration Statement") with the Securities and Exchange Commission (the "SEC").  The Resale Registration Statement registered an aggregate of 17,276,931 common shares in the capital of the Company ("Common Shares") comprised of: (i) up to 4,000,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated April 6, 2026, in the principal amount of US$250,000 and accrued interest (the "April 2026 Promissory Note"); (ii) 6,720,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated May 7, 2026, in the principal amount of US$300,000 and accrued interest (the "May 2026 Promissory Note"); (iii) 4,375,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated June 3, 2026, in the principal amount of US$225,000 and accrued interest (the "June 2026 Promissory Note"); (iv) 272,861 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the April 2026 Promissory Note; (v) 1,127,820 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the May 2026 Promissory Note; and (vi) 781,250 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the June 2026 Promissory Note.

TORONTO and GLIL YAM, Israel, June 3, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor (the "Lender"). Pursuant to a note purchase agreement between the Company and Lender dated June 3, 2026 (the "June Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$225,000, with an original issuance discount of 10% (the "June Note").

TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated.

TORONTO and GLIL YAM, Israel, May 7, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$300,000 convertible note financing in a private placement with an institutional investor, bringing the total gross proceeds raised in recent similar financings to US$550,000. First Note Pursuant to a note purchase agreement between the Company and Lender dated April 6, 2026 (the "First Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$250,000, with an original issuance discount of 10% (the "First Note").

TORONTO and GLIL YAM, Israel, April 10, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.

TORONTO and GLIL YAM, Israel, March 31, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today reported its audited consolidated financial results as of and for the full year ended December 31, 2025. The Company achieved a major operational milestone by generating positive cash flow from operating activities of C$4.7 million for the year ended December 31, 2025, a significant turnaround from negative cash flow in 2024, while delivering high revenue growth in Germany, completing financing transactions, and strengthening its cash position.

TORONTO and GLIL YAM, Israel, March 17, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a medical cannabis company with operations in Israel and Germany, today announced that, following its previous announcement regarding its decision to explore the introduction of additional business activities, it has entered into a non-binding letter of intent (the "LOI") to acquire 51% of Blackaxe Technologies Spolka z Organiczona ("Blackaxe"), a Polish technology company specializing in advanced defense and intelligence solutions. The proposed transaction represents a potential strategic expansion for IMC into the defense and homeland security technology sectors.